keyword
MENU ▼
Read by QxMD icon Read
search

Liver transplant, hcc,

keyword
https://www.readbyqxmd.com/read/28806477/curative-salvage-liver-transplantation-in-cirrhotic-patients-with-hepatocellular-carcinoma-an-intention-to-treat-analysis
#1
Robbert J de Haas, Chetana Lim, Prashant Bhangui, Chady Salloum, Philippe Compagnon, Cyrille Feray, Julien Calderaro, Alain Luciani, Daniel Azoulay
The salvage liver transplantation (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obviate upfront LT, with the 'safety net' of SLT in case of post-resection recurrence. The SLT strategy is successful or curative when patients are recurrence-free following primary resection alone, or after SLT for recurrence. The aim of the current study was to determine the SLT strategy's potential for cure in R&T HCC patients, and to identify predictors for its success...
August 14, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28804572/bacterial-infections-post-living-donor-liver-transplantation-in-egyptian-hepatitis-c-virus-cirrhotic-patients-a-single-center-study
#2
Mohamed F Montasser, Nadia A Abdelkader, Sara M Abdelhakam, Hany Dabbous, Iman F Montasser, Yasmine M Massoud, Waleed Abdelmoaty, Shereen A Saleh, Mohamed Bahaa, Hany Said, Mahmoud El-Meteini
AIM: To determine risk factors, causative organisms and antimicrobial resistance of bacterial infections following living-donor liver transplantation (LDLT) in cirrhotic patients. METHODS: This prospective study included 45 patients with hepatitis C virus-related end-stage liver disease who underwent LDLT at Ain Shams Center for Organ Transplant, Cairo, Egypt from January 2014 to November 2015. Patients were followed-up for the first 3 mo after LDLT for detection of bacterial infections...
July 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28804513/noncirrhotic-hepatocellular-carcinoma-etiology-and-occult-hepatitis-b-virus-infection-in-a-hepatitis-b-virus-endemic-area
#3
Chang Woo Shim, Joong-Won Park, So Hee Kim, Jin Sook Kim, Bo Hyun Kim, Sung Hoon Kim, Eun Kyung Hong
BACKGROUND: Although hepatocellular carcinoma (HCC) usually develops in cirrhotic livers, a minority of cases occur in noncirrhotic livers (NCLs). We investigated etiology, clinicopathological features, and occult hepatitis B virus (HBV) infection (OBI) in patients with NCL HCC in an HBV-endemic area. METHODS: A total of 710 patients who underwent resection or transplantation for HCC at the National Cancer Center (NCC), Korea, were enrolled. HCC and fibrosis stage were diagnosed pathologically...
July 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28802063/hepatitis-b-virus-pregenomic-rna-in-hepatocellular-carcinoma-a-nosological-and-prognostic-determinant
#4
Boris Halgand, Christophe Desterke, Lise Rivière, Guillaume Fallot, Mylène Sebagh, Julien Calderaro, Paulette Bioulac-Sage, Christine Neuveut, Marie-Annick Buendia, Didier Samuel, Cyrille Féray
Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). However, very little is known about the replication of HBV in HCC tissues. PATIENTS AND METHODS: We analysed viral and cellular parameters in HCC (T) and non-tumor liver (NT) samples from 99 HBsAg-positive, virologically suppressed patients treated by tumour resection or liver transplantation. We examined total HBV DNA and RNA as well as covalently closed circular DNA (cccDNA) and pregenomic RNA (pgRNA), which are considered as markers of active HBV replication...
August 12, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28802062/modeling-the-epidemic-of-nonalcoholic-fatty-liver-disease-demonstrates-an-exponential-increase-in-burden-of-disease
#5
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the US, where they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC), and increasingly, an indicator for liver transplantation. METHODS: A Markov model was used to forecast NAFLD disease progression. Incidence of NAFLD was based on historical and projected changes in adult prevalence of obesity and type 2 diabetes mellitus (DM)...
August 12, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28798283/healthcare-costs-for-chronic-hepatitis-c-in-south-korea-from-2009-to-2013-an-analysis-of-the-national-health-insurance-claims-data
#6
Moran Ki, Hwa Young Choi, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong
Background/Aims: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are therefore essential for creating policies and expanding drug access. Herein, we aimed to investigate the number of HCV-related liver disease patients, their healthcare utilization, their annual direct medical costs, and the interferon-based antiviral treatment rates and costs from 2009 to 2013 in South Korea...
August 14, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28795982/treatment-of-patients-with-hepatitis-c-virus-infection-genotype-4-with-ledipasvir-sofosbuvir-in-the-liver-transplant-setting
#7
Faisal Abaalkhail, Hussein Elsiesy, Hany Elbeshbeshy, Mohamed Shawkat, Sarra Yousif, Waheed Ullah, Saleh Alabbad, Ahmed Al-Jedai, Aziza Ajlan, Dieter Broering, Sammy Saab, Mohammed Al Sebayel, Waleed Al-Hamoudi
BACKGROUND: Hepatitis C virus infection is a major cause of liver cirrhosis and hepatocellular carcinoma and the leading indication for liver transplantation. In the Middle East, genotype 4 HCV infection is the most common genotype. However, limited data exists on the treatment of genotype-4 in the liver transplant setting. We evaluated the safety and efficacy of ledipasvir-sofosbuvir (LDV/SOF) in treating HCV genotype-4 infected patients with cirrhosis or postliver transplantation. METHODS: This prospective, single-arm, observational study includes cohort of patients with cirrhosis before liver transplantation (Cohort A) and a cohort of postliver transplantation patients (Cohort B)...
August 9, 2017: Transplantation
https://www.readbyqxmd.com/read/28791798/cost-effectiveness-analysis-of-potentially-curative-and-combination-treatments-for-hepatocellular-carcinoma-with-person-level-data-in-a-canadian-setting
#8
Hla-Hla Thein, Wanrudee Isaranuwatchai, Yao Qiao, Kenny Wong, Gonzalo Sapisochin, Kelvin K W Chan, Eric M Yoshida, Craig C Earle
Patients with early-stage hepatocellular carcinoma (HCC) are potential candidates for curative treatments such as radiofrequency ablation (RFA), surgical resection (SR), or liver transplantation (LT), which have demonstrated a significant survival benefit. We aimed to estimate the cost-effectiveness of curative and combination treatment strategies among patients diagnosed with HCC during 2002-2010. This study used Ontario Cancer Registry-linked administrative data to estimate effectiveness and costs (2013 USD) of the treatment strategies from the healthcare payer's perspective...
August 8, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28780679/locoregional-therapies-for-hepatocellular-carcinoma-and-the-new-li-rads-treatment-response-algorithm
#9
Ania Kielar, Kathryn J Fowler, Sara Lewis, Vahid Yaghmai, Frank H Miller, Hooman Yarmohammadi, Charles Kim, Victoria Chernyak, Takeshi Yokoo, Jeffrey Meyer, Isabel Newton, Richard K Do
Radiologists play a central role in the assessment of patient response to locoregional therapies for hepatocellular carcinoma (HCC). The identification of viable tumor following treatment guides further management and potentially affects transplantation eligibility. Liver Imaging Reporting and Data Systems (LI-RADS) first introduced the concept of LR-treated in 2014, and a new treatment response algorithm is included in the 2017 update to assist radiologists in image interpretation of HCC after locoregional therapy...
August 5, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28776121/liver-transplantation-for-hepatocellular-carcinoma-kent-hospital-experience
#10
Cahit Yılmaz
No abstract text is available yet for this article.
August 4, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28774261/modelling-the-burden-of-hepatitis-c-infection-among-people-who-inject-drugs-in-norway-1973-2030
#11
Hinta Meijerink, Richard A White, Astrid Løvlie, Birgitte Freiesleben de Blasio, Olav Dalgard, Ellen J Amundsen, Espen Melum, Hilde Kløvstad
BACKGROUND: Lack of Hepatitis C virus (HCV) incidence data in (Norwegian) high-risk groups impedes the ability to make informed decisions on prevention measures. Thus we rely on modelling to estimate the incidence and burden of HCV infections. METHODS: We constructed a compartmental model for HCV infections in Norway among active and former people who inject drugs (PWIDs). We based yearly transition rates on literature. The model was fitted to absolute numbers of hepatitis C associated cirrhosis, hepatocellular carcinoma (HCC) and death from national data sources (2000-2013)...
August 3, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28771543/population-based-prevalence-incidence-and-disease-burden-of-autoimmune-hepatitis-in-south-korea
#12
Bo Hyun Kim, Hwa Young Choi, Moran Ki, Kyung-Ah Kim, Eun Sun Jang, Sook-Hyang Jeong
BACKGROUND AND AIM: Little is known about population-based epidemiology and disease burden of autoimmune hepatitis (AIH). The aim of this study was to investigate the prevalence, incidence, comorbidity and direct medical cost of AIH in South Korea. METHODS: The data was from the nationwide, population-based National Health Insurance Service claims database and the Rare Intractable Disease registration program. Age and gender-specific prevalence rates were calculated, and data on comorbidity, diagnostic tests, prescribed drugs, and medical costs were retrieved for patients registered under the disease code K75...
2017: PloS One
https://www.readbyqxmd.com/read/28768371/minimal-hepatic-encephalopathy-identifies-patients-at-risk-of-faster-cirrhosis-progression
#13
Javier Ampuero, Carmina Montoliú, Macarena Simón-Talero, Virginia Aguilera, Raquel Millán, Celina Márquez, Rodrigo Jover, María Carmen Rico, Carmen Sendra, Miguel Ángel Serra, Manuel Romero-Gómez
BACKGROUND &AIM: Minimal hepatic encephalopathy (MHE) predicts poor prognosis and could reflect an advanced liver disease. We aimed to assess whether MHE could be a surrogate marker of a further liver disease. METHODS: Prospective multicenter study including 320 cirrhotic patients, followed for up to 5 years, which were classified at baseline in: compensated cirrhosis without (stage 1) and with varices (stage 2), one decompensating event (stage 3), any second decompensating event (stage 4)...
August 2, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28761617/hepatocellular-carcinoma-a-clinicopathological-study-of-64-cases
#14
Faten Limaiem, Marwa Bouhamed, Ghada Sahraoui, Sabeh Mzabi
Hepatocellular carcinoma (HCC) is the most common of all liver cancers and is a major worldwide public health problem. The aim of this study was to provide an updated overview on clinicopathological features, treatment and outcome of HCC. In our retrospective study, we reviewed 64 cases of HCC that were diagnosed at the pathology department of Mongi Slim hospital over a fifteen-year period (2000- 2014). Relevant clinical information and microscopic slides were retrospectively reviewed. Our study group included 38 men and 26 women (sex ratio M/F = 1,26) aged between 8 and 83 years (mean = 56,64 years)...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28756056/healthcare-costs-related-to-treatment-of-hepatocellular-carcinoma-among-veterans-with-cirrhosis-in-the-united-states
#15
David E Kaplan, Michael K Chapko, Rajni Mehta, Feng Dai, Melissa Skanderson, Ayse Aytaman, Michelle Baytarian, Kathryn D'Addeo, Rena Fox, Kristel Hunt, Christine Pocha, Adriana Valderrama, Tamar H Taddei
BACKGROUND & AIMS: It is important to quantify medical costs associated with hepatocellular carcinoma (HCC), the incidence of which is rapidly increasing incidence in the United States, for development of rational healthcare policies related to liver cancer surveillance and treatment of chronic liver disease. We aimed to comprehensively quantify healthcare costs for HCC among patients with cirrhosis in an integrated health system and develop a model for predicting costs based on clinically relevant variables...
July 26, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28755240/bridging-to-liver-transplantation-in-hcc-patients
#16
REVIEW
Dagmar Kollmann, Nazia Selzner, Markus Selzner
BACKGROUND: Liver transplantation (LT) is the only cure for patients diagnosed with unresectable hepatocellular carcinoma (HCC), and HCC has become the leading indication for LT in the USA. The shortage of liver grafts results in a significant waiting time for LT with the risk of tumour progression. Treating HCCs during the waiting time prior to transplantation (bridging therapy) is an attractive strategy to reduce the risk of exceeding the tumour criteria for transplantation. Studies on bridging therapy are heterogenous and due to ethical issues, mostly of retrospective design...
July 28, 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/28755196/the-qu%C3%A3-bec-ntbc-study
#17
Fernando Alvarez, Suzanne Atkinson, Manon Bouchard, Catherine Brunel-Guitton, Daniela Buhas, Jean-François Bussières, Josée Dubois, Daphna Fenyves, Paul Goodyer, Martyne Gosselin, Ugur Halac, Patrick Labbé, Rachel Laframboise, Bruno Maranda, Serge Melançon, Aicha Merouani, Grant A Mitchell, John Mitchell, Guy Parizeault, Luc Pelletier, Véronique Phan, Jean-François Turcotte
In this chapter we describe the current Quebec NTBC Study protocol. Quebec's unique characteristics have influenced the development of the protocol, including a high prevalence of hepatorenal tyrosinemia (HT1), universal newborn screening for HT1, availability of treatment with nitisinone (NTBC) and special diet, a large territory, where HT1 treatment is coordinated by a small number of centers. Screened newborns are seen within 3 weeks of birth. Patients with liver dysfunction (prolonged prothrombin time and/or international normalized ratio (INR) provide sensitive, rapidly available indicators) are treated by NTBC and special diet...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28755185/the-liver-in-tyrosinemia-type-i-clinical-management-and-course-in-quebec
#18
Ugur Halac, Josée Dubois, Grant A Mitchell
HT1 is a severe autosomal recessive disorder due to the deficiency of fumarylacetoacetate hydrolase (FAH), the final enzyme in the degradation of tyrosine. Before the era of treatment with 2-(2-N-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), even with newborn screening and optimal diet therapy, HT1 patients often developed liver failure. Death was common in patients who did not undergo liver transplantation. For the last two decades, NTBC has revolutionized the management of HT1 patients. In screened newborns treated within the first month of life, we have not observed hepatocarcinoma...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28755181/biochemical-and-clinical-aspects-of-hereditary-tyrosinemia-type-1
#19
Geneviève Morrow, Robert M Tanguay
Inborn errors of metabolism (IEMs) are a group of diseases involving a genetic defect that alters a metabolic pathway and that presents usually during infancy. The tyrosine degradation pathway contains five enzymes, four of which being associated with IEMs. The most severe metabolic disorder associated with this catabolic pathway is hereditary tyrosinemia type 1 (HT1; OMIM 276700). HT1 is an autosomal recessive disease caused by a deficiency of fumarylacetoacetate hydrolase (FAH), the last enzyme of the tyrosine catabolic pathway...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28750141/hepatocellular-carcinoma-in-patients-with-chronic-hepatitis-c-and-cirrhosis-in-denmark-a-nationwide-cohort-study
#20
Sofie Hallager, Steen Ladelund, Mette S Kjaer, Lone G Madsen, Erika Belard, Alex Lund Laursen, Jan Gerstoft, Birgit T Røge, Karin E Grønbaek, Henrik B Krarup, Peer B Christensen, Nina Weis
Cirrhosis in patients with chronic hepatitis C increases the risk of hepatocellular carcinoma (HCC) and surveillance with ultrasound (US) and alpha-fetoprotein (AFP) is recommended. This study aimed to estimate changes in the HCC incidence rate (IR) over time, HCC stage and prognosis, and AFP and US performed in patients with hepatitis C and cirrhosis. Eligible patients were identified in the Danish Database for Hepatitis B and C and data from national health registries and patient charts were obtained. Tumor stage was based on Barcelona-Clinic Liver Cancer stage, TNM classification and size and number of lesions combined into stage 0 - 3...
July 27, 2017: Journal of Viral Hepatitis
keyword
keyword
28620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"